RXi went public [3] and in 2009 the company filed a patent for its unique INTASYL technology, a self-delivering RNAi platform.
RXi focused on the discovery of RNAi applications for dermatological and ocular therapies.
The company’s name was changed to Phio Pharmaceuticals in November 2018 [4] to reflect its transition from a platform company to one committed to discovering immuno-oncology therapeutics based on its self-delivering RNAi platform.
[5] Phio's technology platform (INTASYL) allows the development of 'self-delivering’ RNAi compounds, or 'sd-rxRNA' for short, in which drug-like properties were built into the RNAi compound itself, rather than relying on liposomal delivery to improve circulation time and cellular uptake.
The result is spontaneous uptake in multiple cell types in vitro and in vivo.